- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 7 of 9.
EudraCT Number: 2009-014846-26 | Sponsor Protocol Number: CLBH589E2301 | Start Date*: 2010-05-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high do... | |||||||||||||
Medical condition: Patients with classical Hodgkine's Lymphoma (HL), who achieved a complete response following high dose chemotherapy (HDT) and autologous stem cell transplant (AHSCT). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) GB (Completed) NL (Completed) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000743-34 | Sponsor Protocol Number: C-935788-011 | Start Date*: 2008-06-18 | |||||||||||
Sponsor Name:Rigel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002082-19 | Sponsor Protocol Number: LAQ-MS-306 | Start Date*: 2013-11-25 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000418-75 | Sponsor Protocol Number: TV5600-CNS-20007 | Start Date*: 2014-11-18 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients... | |||||||||||||
Medical condition: Huntington's Disease (HD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004079-11 | Sponsor Protocol Number: D5495C00002 | Start Date*: 2019-06-28 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia | ||
Medical condition: Chronic kidney disease and hyperuricaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) CZ (Completed) ES (Ongoing) IT (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000226-38 | Sponsor Protocol Number: 156-13-210 | Start Date*: 2015-01-08 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects ... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) SE (Completed) HU (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003089-38 | Sponsor Protocol Number: FG001-CT-001 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:FluoGuide A/S | |||||||||||||
Full Title: An open-label, dose escalation, single-dose administration, multi-center phase I/II trial of FG001 (an imaging agent), in patients with glioblastoma scheduled for neurosurgery | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014796-51 | Sponsor Protocol Number: 120BC201 | Start Date*: 2010-02-02 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n... | |||||||||||||
Medical condition: Advanced Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003623-37 | Sponsor Protocol Number: CAN-PDP | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: CANnabidiol for Parkinson’s Disease Psychosis | |||||||||||||
Medical condition: Parkinson's disease psychosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002240-40 | Sponsor Protocol Number: I4T-MC-JVCU | Start Date*: 2015-04-10 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal ... | |||||||||||||
Medical condition: Metastatic gastric adenocarcinoma or gastroesophageal junction (GEJ) denocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) FI (Completed) NL (Completed) IT (Completed) ES (Completed) PL (Completed) BE (Completed) GB (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002181-38 | Sponsor Protocol Number: WARCEF | Start Date*: 2004-10-22 |
Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke | ||
Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction. | ||
Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004269-96 | Sponsor Protocol Number: IG8801CLBP201 | Start Date*: 2016-02-24 | |||||||||||
Sponsor Name:Gador S.A. | |||||||||||||
Full Title: A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with... | |||||||||||||
Medical condition: non-specific Chronic Low Back Pain persisting for at least 3 months | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006872-39 | Sponsor Protocol Number: DIMS4 | Start Date*: 2008-01-04 | |||||||||||||||||||||
Sponsor Name:Daval International Limited | |||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis | |||||||||||||||||||||||
Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002607-18 | Sponsor Protocol Number: 101.04 | Start Date*: 2012-08-30 | |||||||||||
Sponsor Name:Marius Henriksen | |||||||||||||
Full Title: COMBINED INTRA ARTICULAR CORTICOSTEROID AND EXERCISE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMISED TRIAL | |||||||||||||
Medical condition: Knee Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004941-27 | Sponsor Protocol Number: M10-440 | Start Date*: 2009-03-11 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma | |||||||||||||
Medical condition: Metastatic Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000970-31 | Sponsor Protocol Number: CV013-034 | Start Date*: 2018-09-10 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8 Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Function Given... | ||||||||||||||||||
Medical condition: Heart failure with reduced ejection fraction (HFrEF) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004155-39 | Sponsor Protocol Number: BAY1000394/14858 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer | |||||||||||||
Medical condition: Subjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001013-16 | Sponsor Protocol Number: PRODIGE69 | Start Date*: 2020-07-20 |
Sponsor Name:CHU DIJON | ||
Full Title: FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WI... | ||
Medical condition: METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004857-86 | Sponsor Protocol Number: CTP_CAP001 | Start Date*: 2007-01-19 | |||||||||||
Sponsor Name:Caprion Pharmaceuticals Inc. | |||||||||||||
Full Title: A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidne... | |||||||||||||
Medical condition: metastatic kidney cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000163-31 | Sponsor Protocol Number: RH-FG001-001 | Start Date*: 2023-03-27 | ||||||||||||||||
Sponsor Name:Copenhagen University | ||||||||||||||||||
Full Title: An open-label, non-randomized, single dose, phase II trial of FG001 (an optical imaging agent) for localization of Meningiomas or presumed Low-Grade Gliomas scheduled for neurosurgery | ||||||||||||||||||
Medical condition: Meningioma and lowgrade glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
